Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

By LabMedica International staff writers
Posted on 05 Oct 2026

Fungal bloodstream infections pose a major threat to hospitalized patients. More...

Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream infections. Because fungal species can differ in their response to antifungal drugs, delayed identification can hinder timely targeted therapy. To accelerate species-level identification, researchers have introduced a genomic workflow that detects fungal pathogens from blood culture samples before conventional systems turn positive.

Chiba University (Chiba, Japan) researchers developed a workflow based on random PCR-based nanopore whole-genome sequencing for faster identification of fungal bloodstream infections. The approach analyzes blood culture samples while they are still incubating, before automated culture systems flag them as positive. The study was published online in Microbiology Spectrum on August 21, 2026.

The workflow begins by selectively breaking down human cells and degrading human DNA with benzonase, while leaving fungal and bacterial DNA unaffected. This increases the proportion of microbial DNA in the sample. Researchers then use PCR-based whole-genome amplification to generate enough genetic material for sequencing. Amplified DNA is loaded onto a portable nanopore sequencing device, which produces DNA sequence data in real time and allows comparison with a custom reference database of fungal and bacterial bloodstream pathogens.

In testing with 48 clinical blood culture samples representing eight fungal species, the workflow achieved species-level identification within approximately seven hours. The method identified pathogens including Candida albicans, Nakaseomyces glabratus, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans. It also detected mixed infections involving two fungal species or both fungi and bacteria. 

Because the workflow captures the full genome of the pathogen, it can also detect genetic variants in genes associated with drug resistance. The researchers noted that further work is needed to determine optimal sample collection timing during incubation. They also identified a need to improve detection when heavy bacterial growth masks fungal signals in mixed infections.

“I have a background in sequence analysis and genomics, and I saw an opportunity to apply my expertise to the important clinical challenge of fungal infections. I was particularly motivated by the possibility of using modern genomic technologies to improve our understanding, diagnosis, and ultimately treatment of these infections,” said Hiroki Takahashi, professor at the Medical Mycology Research Center of Chiba University.

“Our method may enable clinicians to initiate appropriate antifungal treatment earlier, potentially improving outcomes for patients with life-threatening fungal bloodstream infections,” added Prof. Takahashi.

Related Links
Chiba University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.